Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

S&P Consultants Ranked in the Best in KLAS: Software and Services Report for Fourth Consecutive Year

Published

on

Reading Time: 4 minutes

BRAINTREE, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/HealthIT?src=hash” target=”_blank”gt;#HealthITlt;/agt;–With the release of the 2019 Best in KLAS: Software Services report,
S&P Consultants marks the fourth year of being ranked by the
prestigious peer-reviewed healthcare technology organization.

To assemble the report, KLAS talks to thousands of organizations to
gather insight on their implementation experiences with a variety of
vendors and how well those vendors live up to expectations.

“Of the many accolades available to businesses in our sector, this one
is particularly meaningful,” said Andy Splitz, Cofounder and CEO of S&P
Consultants. “That’s because it represents the opinions of our
clients—and their peer set. These are people who have had direct
experience in implementing HIT solutions and working with some of the
best consultants and software vendors in the industry. For them to
single us out this way again this year is not only very gratifying, but
it’s also highly motivating to our hard-working team.”

This year, S&P was rated in the HIT Implementation Support and Staffing
category with a score of 92.9 out of 100.

As part of KLAS’s research, candid and anonymized feedback from
confirmed S&P clients collected. Many of the comments provided by S&P
clients spoke to how our expertise helped all parties in the
implementation achieve their common goal. Here are some highlights1:

  • S&P Consultants helped steer us away from danger and… set us up
    much better for future success

    Director, Project Results –
    Aug 2018.
  • S&P Consultants helped us figure out things that our EHR vendor said
    were impossible. And we and S&P Consultants also figured out other
    things together. That was quite an accomplishment. S&P Consultants
    really did partner with us, and they helped us through the entire
    project.
    Manager, Project Results – Dec 2018
  • I would contract with S&P Consultants again in a heartbeat. We liked
    that they were willing to tell us what we needed to hear. Some of the
    other consultants we have worked with would sometimes tell us what we
    wanted to hear. But S&P Consultants was a little different. I could
    tell right out of the gate that they were up front and that they did
    things in a great manner. They were great about telling us how things
    were. Also, the people that S&P Consultants gave us were tremendous.
    They were head and shoulders above the folks that we were getting from
    another vendor. S&P Consultants has a good methodology. They use a
    methodology and structure for implementations that are based on some
    of their previous engagements. For us, the methodology was a huge
    difference from what we had with another vendor. When we brought S&P
    Consultants into our implementation, there was a night-and-day
    difference. In general, S&P Consultants’ people, framework, and
    ability to have candid conversations were the things that set them
    apart.

    Director, Project – Jan 2019

  • S&P Consultants didn’t come with an attitude of telling us what they
    have done and what we have to do. They actually learned our operation
    as much as possible. They were able to integrate what they knew with
    our workflow. I was really impressed.

    Manager, Tools and
    Methodology – Dec 2018

  • I was struck by the fact that S&P Consultants was able to initiate
    activity and work without having to be told. They weren’t sitting
    around waiting for directions. They integrated with our staff and
    essentially became part of our staff. And they were the subject matter
    experts for us. S&P Consultants worked very closely with our teams,
    and they always had new things that needed to get done. They would
    initiate things.
    Manager, People and Knowledge – Dec 2018
  • The biggest thing that sets S&P Consultants apart is the fact that
    their people are extremely comfortable working in a client’s
    environment. Some consultants just talk around a table in the
    conference room. But S&P Consultants’ people don’t just stay at the
    table. They are out in the trenches working with the team. They go
    where they are needed. That really stands out. They show us how to do
    the things they talk about. The consultants made our folks
    comfortable. Our staff members look forward to the consultants coming
    on-site. People come up to me and ask whether the consultants are
    coming in.
    Manager, People and Knowledge – Dec 2018

Zach Johnson, S&P’s Chief Strategy Officer, lays much of the
firm’s success at the feet of its proven implementation methodology
known as S&P InTegrity™.

“InTegrity is a unique approach to HIT implementations that helps
clients ensure their team’s success, deliver the highest-quality result,
and maximize their ROI. InTegrity gives clients better visibility into
the potential (common) pitfalls that lay in wait for many
implementations. The process also helps client bind strategy to
execution, ensuring that they are leveraging technology to serve both
their clinical and revenue goals at the highest levels. Our approach
adds a level of granularity and client-specificity to the vendor’s
general framework, so that real-world conditions are taken into account.
InTegrity accurately reflects the actual situation, resources,
leadership, objectives and day-to-day reality in a way that greatly
improves the chances for a smooth and successful implementation.”

About S&P Consultants:
S&P Consultants enjoys a 20-year
reputation for “doing the right thing” in healthcare IT, facilitating
realistic interactions among all parties in HIS implementations. Their
InTegrity℠ approach provides a solid “genetic roadmap” and adaptive
framework to organizations looking to assure the success of complex
projects.

About KLAS:
KLAS is a data-driven company on a mission to improve
the world’s healthcare by enabling provider and payer voices to be heard
and counted. Working with thousands of healthcare professionals, KLAS
collects insights on software, services and medical equipment to deliver
reports, trending data and statistical overviews. KLAS data is accurate,
honest and impartial. The research directly reflects the voice of
healthcare professionals and acts as a catalyst for improving vendor
performance. To learn more about KLAS and the insights we provide, visit KLASresearch.com.

1 – Selected commentary collected about S&P Consultants. ©
KLAS 2019 visit https://klasresearch.com
for a complete view.

Contacts

S&P Consultants
Tracey Leathers
781-428-3497
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland

Published

on

Continue Reading

Cannabis

Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa

Published

on

Continue Reading

Innocan

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Published

on

innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial:-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey

HERZLIYA, Israel and ALGARY, AB, May 9, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan’s innovative therapy provided immediate noticeable pain relief and improved mobility.

Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb. Consequently, she developed laminitis in her left front limb, an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. Over time, Miri’s condition worsened, culminating in the formation of a abscess in the affected hoof, which appeared to have intensified her pain. Despite receiving pain relief medications, Miri found no respite, was unable to move, and her caregivers were advised to euthanize her.

As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection. The effect was immediate, with Miri becoming active and roaming the farm. Following the liposomal-CBD injection, the abscess in her affected foot healed, and Miri regained her ability to walk and move as she did before her laminitis developed.

“Thanks to our innovative liposomal-CBD injection, we are thrilled to have brought relief to Miri, eliminating the need for euthanasia,” commented Iris Bincovich, CEO of Innocan. “Once again, Innocan has shown liposomal-CBD to be effectively active for pain relief and well-being. We see this pre-clinical treatment as strong evidence of liposomal-CBD’s potential to improve the lives of animal patients and potentially human patients.”

“Laminitis is a crippling condition well familiar and common in horses,” said Prof Chezy Barenholz, the Chief Scientific Officer of Innocan. “The disease results in severe pain condition, representing another big market for liposomal-CBD with great potential to treat horses. Innocan is dedicated to advancing the development of CBD-based therapeutics for various indications in both humans and animals.”

For further information and a supporting video, please see: https://youtu.be/Hgqh2WOlwJQ?si=oGgSYrGi3rkW-RC

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+1 5162104025

+972-54-3012842

+442037699377

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey-302141590.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania